Evaluating the frequency of autoantibodies in patients with chronic hepatitis b
Viral Hepatitis Journal, cilt.26, sa.1, ss.14-21, 2020 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 1
- Basım Tarihi: 2020
- Doi Numarası: 10.4274/vhd.galenos.2020.2019.0035
- Dergi Adı: Viral Hepatitis Journal
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.14-21
- Anahtar Kelimeler: Hepatosteatosis, chronic hepatitis B, autoantibody
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objectives: The objective of this study is to evaluate the frequency of autoantibodies retrospectively in newly diagnosed chronic hepatitis B (CHB) patients. Materials and Methods: The study was retrospectively conducted in between Jan 2010 and August 2015 in a research and training hospital in Istanbul with 122 patients (ages of 17-80) consulted to Gastroenterology and Infection Diseases and diagnosed with CHB and 117 healthy control group. In both groups, positive and negative rates of anti-nuclear antibody (ANA), anti-smooth muscle antibody (ASMA), anti-mitochondrial antibody (AMA) and anti-liver-kidney mitochondrial antibody (anti-LKM) were compared. Results: No AMA and LKM1 were observed in any patient or control groups. ANA result was positive in 9.8% of the patient group and 8.5% of the control group; and there was no statistically significant difference between them (p>0.05). ASMA result was positive in 5.7% of the patient group and 0.9% of the control group; and the difference between them was very close to significance but statistically not enough to be significant (p>0.05). Hepatosteatosis level of the patient group was significantly lower than the control group, statistically (p<0.05). Conclusion: In this study, it is concluded that the low frequency of autoantibody may depend on the fact that it was only examined in CHB patients who are not receiving any treatment. Examination of autoantibodies in newly diagnosed chronic hepatitis B patients before and after treatment may provide insight in terms of occuring autoimmune phenomena cases and extrahepatic findings.